201 related articles for article (PubMed ID: 34229670)
1. Piperlongumine inhibits migration and proliferation of castration-resistant prostate cancer cells via triggering persistent DNA damage.
Zhang DF; Yang ZC; Chen JQ; Jin XX; Qiu YD; Chen XJ; Shi HY; Liu ZG; Wang MS; Liang G; Zheng XH
BMC Complement Med Ther; 2021 Jul; 21(1):195. PubMed ID: 34229670
[TBL] [Abstract][Full Text] [Related]
2. Chalcone Derivatives Suppress Proliferation and Migration of Castration-resistant Prostate Cancer Cells Through FAK-mediated DNA Damage.
Xiao H; Wu Z; Wang Q; Zhou C; Lu F; Xiao Y
Anticancer Res; 2023 Jan; 43(1):389-403. PubMed ID: 36585202
[TBL] [Abstract][Full Text] [Related]
3. Rooibos suppresses proliferation of castration-resistant prostate cancer cells via inhibition of Akt signaling.
Huang SH; Tseng JC; Lin CY; Kuo YY; Wang BJ; Kao YH; Muller CJF; Joubert E; Chuu CP
Phytomedicine; 2019 Nov; 64():153068. PubMed ID: 31419729
[TBL] [Abstract][Full Text] [Related]
4. Mechanistic study of dual-function inhibitors targeting topoisomerase II and Rad51-mediated DNA repair pathway against castration-resistant prostate cancer.
Chiang YC; Leu WJ; Chen YC; Ye PC; Hsu YT; Hsiao YC; Hsu JL; Chan SH; Hsu LC; Huang HS; Guh JH
Prostate; 2023 Dec; 83(16):1549-1563. PubMed ID: 37583103
[TBL] [Abstract][Full Text] [Related]
5. The discovery of novel sanjuanolide derivatives as chemotherapeutic agents targeting castration-resistant prostate cancer.
Wang G; Chen X; Wang N; Xiao Y; Shu S; Alsayed AMM; Liu L; Ma Y; Liu P; Zhang Q; Chen X; Liu Z; Zheng X
Bioorg Chem; 2021 Jun; 111():104880. PubMed ID: 33839585
[TBL] [Abstract][Full Text] [Related]
6. A novel HDAC6 inhibitor interferes microtubule dynamics and spindle assembly checkpoint and sensitizes cisplatin-induced apoptosis in castration-resistant prostate cancer.
Ye PC; Leu WJ; Yeh TY; Hsu YT; Lin YC; Wei ZY; Chen YC; Chiang YC; Hsu JL; Chan SH; Hsu LC; Chern JW; Yu CW; Guh JH
Prostate; 2024 May; 84(6):605-619. PubMed ID: 38375594
[TBL] [Abstract][Full Text] [Related]
7. Corosolic acid, a natural triterpenoid, induces ER stress-dependent apoptosis in human castration resistant prostate cancer cells via activation of IRE-1/JNK, PERK/CHOP and TRIB3.
Ma B; Zhang H; Wang Y; Zhao A; Zhu Z; Bao X; Sun Y; Li L; Zhang Q
J Exp Clin Cancer Res; 2018 Sep; 37(1):210. PubMed ID: 30176898
[TBL] [Abstract][Full Text] [Related]
8. Combination with vorinostat enhances the antitumor activity of cisplatin in castration-resistant prostate cancer by inhibiting DNA damage repair pathway and detoxification of GSH.
Chang T; Lian Z; Ma S; Liang Z; Ma X; Wen X; Wang Y; Liu R
Prostate; 2023 Apr; 83(5):470-486. PubMed ID: 36576015
[TBL] [Abstract][Full Text] [Related]
9. Repurposing of phentolamine as a potential anticancer agent against human castration-resistant prostate cancer: A central role on microtubule stabilization and mitochondrial apoptosis pathway.
Ho CH; Hsu JL; Liu SP; Hsu LC; Chang WL; Chao CC; Guh JH
Prostate; 2015 Sep; 75(13):1454-66. PubMed ID: 26180030
[TBL] [Abstract][Full Text] [Related]
10. Piperlongumine potentiates the antitumor efficacy of oxaliplatin through ROS induction in gastric cancer cells.
Zhang P; Shi L; Zhang T; Hong L; He W; Cao P; Shen X; Zheng P; Xia Y; Zou P
Cell Oncol (Dordr); 2019 Dec; 42(6):847-860. PubMed ID: 31493144
[TBL] [Abstract][Full Text] [Related]
11. PDLIM2 suppression efficiently reduces tumor growth and invasiveness of human castration-resistant prostate cancer-like cells.
Kang M; Lee KH; Lee HS; Park YH; Jeong CW; Ku JH; Kim HH; Kwak C
Prostate; 2016 Feb; 76(3):273-85. PubMed ID: 26499308
[TBL] [Abstract][Full Text] [Related]
12. Ascleposide, a natural cardenolide, induces anticancer signaling in human castration-resistant prostatic cancer through Na
Leu WJ; Wang CT; Hsu JL; Chen IS; Chang HS; Guh JH
Prostate; 2020 Mar; 80(4):305-318. PubMed ID: 31905252
[TBL] [Abstract][Full Text] [Related]
13. DNA repair pathways-targeted cyclovirobuxine inhibits castration-resistant prostate cancer growth by promoting cell apoptosis and cycle arrest.
Gao K; Zhu S; Shao Q; Qi Y; Zhang C; Li X; Guo J; Wu G; Jiang H
Transl Oncol; 2023 Sep; 35():101708. PubMed ID: 37406549
[TBL] [Abstract][Full Text] [Related]
14. Melittin inhibits tumor cell migration and enhances cisplatin sensitivity by suppressing IL-17 signaling pathway gene LCN2 in castration-resistant prostate cancer.
Yan R; Dai W; Mao Y; Yu G; Li W; Shu M; Xu B
Prostate; 2023 Nov; 83(15):1430-1445. PubMed ID: 37517867
[TBL] [Abstract][Full Text] [Related]
15. Aspalathin-rich green Aspalathus linearis extract suppresses migration and invasion of human castration-resistant prostate cancer cells via inhibition of YAP signaling.
Huang SH; Kao YH; Muller CJF; Joubert E; Chuu CP
Phytomedicine; 2020 Apr; 69():153210. PubMed ID: 32217447
[TBL] [Abstract][Full Text] [Related]
16. Piperlongumine increases the apoptotic effect of doxorubicin and paclitaxel in a cervical cancer cell line.
Seber S; Sirin DY; Yetisyigit T; Bilgen T
Niger J Clin Pract; 2020 Mar; 23(3):386-391. PubMed ID: 32134040
[TBL] [Abstract][Full Text] [Related]
17. Synergistic anticancer activity of doxorubicin and piperlongumine on DU-145 prostate cancer cells - The involvement of carbonyl reductase 1 inhibition.
Piska K; Koczurkiewicz P; Wnuk D; Karnas E; Bucki A; Wójcik-Pszczoła K; Jamrozik M; Michalik M; Kołaczkowski M; Pękala E
Chem Biol Interact; 2019 Feb; 300():40-48. PubMed ID: 30611789
[TBL] [Abstract][Full Text] [Related]
18. Targeting NPRL2 to enhance the efficacy of Olaparib in castration-resistant prostate cancer.
Chen X; Chen Z; Zheng B; Tang W
Biochem Biophys Res Commun; 2019 Jan; 508(2):620-625. PubMed ID: 30522863
[TBL] [Abstract][Full Text] [Related]
19. Doxycycline synergizes with doxorubicin to inhibit the proliferation of castration-resistant prostate cancer cells.
Zhu C; Yan X; Yu A; Wang Y
Acta Biochim Biophys Sin (Shanghai); 2017 Nov; 49(11):999-1007. PubMed ID: 28985240
[TBL] [Abstract][Full Text] [Related]
20. Effect of FAK inhibitor VS-6063 (defactinib) on docetaxel efficacy in prostate cancer.
Lin HM; Lee BY; Castillo L; Spielman C; Grogan J; Yeung NK; Kench JG; Stricker PD; Haynes AM; Centenera MM; Butler LM; Shreeve SM; Horvath LG; Daly RJ
Prostate; 2018 Mar; 78(4):308-317. PubMed ID: 29314097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
